173 related articles for article (PubMed ID: 19028718)
1. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?
Blondeau JM
J Antimicrob Chemother; 2009 Feb; 63(2):238-42. PubMed ID: 19028718
[TBL] [Abstract][Full Text] [Related]
2. Established and potential risk factors for Clostridum difficile infection.
Vaishnavi C
Indian J Med Microbiol; 2009; 27(4):289-300. PubMed ID: 19736396
[TBL] [Abstract][Full Text] [Related]
3. Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Risk of
Li D; Song Y; Bai Z; Xi X; Liu F; Zhang Y; Qin C; Du D; Du Q; Liu S
Antibiotics (Basel); 2023 Jun; 12(7):. PubMed ID: 37508205
[TBL] [Abstract][Full Text] [Related]
4.
Datta AK; Debnath P; Chakraborty U; Chandra A
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33462050
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Mohsen S; Dickinson JA; Somayaji R
Can Fam Physician; 2020 Sep; 66(9):e228-e237. PubMed ID: 32933991
[TBL] [Abstract][Full Text] [Related]
6. Update on the adverse effects of antimicrobial therapies in community practice.
Mohsen S; Dickinson JA; Somayaji R
Can Fam Physician; 2020 Sep; 66(9):651-659. PubMed ID: 32933978
[TBL] [Abstract][Full Text] [Related]
7. Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin.
Chang C
Clin Exp Gastroenterol; 2018; 11():335-345. PubMed ID: 30288076
[TBL] [Abstract][Full Text] [Related]
8. Prolonged Mechanical Ventilation Assistance Interacts Synergistically with Carbapenem for
Chiang SR; Lai CC; Ho CH; Chen CM; Chao CM; Wang JJ; Cheng KC
J Clin Med; 2018 Aug; 7(8):. PubMed ID: 30127264
[TBL] [Abstract][Full Text] [Related]
9. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.
Pimentel M; Cash BD; Lembo A; Wolf RA; Israel RJ; Schoenfeld P
Dig Dis Sci; 2017 Sep; 62(9):2455-2463. PubMed ID: 28589238
[TBL] [Abstract][Full Text] [Related]
10. Surgical prophylaxis with gentamicin and acute kidney injury: a systematic review and meta-analysis.
Srisung W; Teerakanok J; Tantrachoti P; Karukote A; Nugent K
Ann Transl Med; 2017 Mar; 5(5):100. PubMed ID: 28361065
[TBL] [Abstract][Full Text] [Related]
11. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
[TBL] [Abstract][Full Text] [Related]
12. Ciprofloxacin Affects Host Cells by Suppressing Expression of the Endogenous Antimicrobial Peptides Cathelicidins and Beta-Defensin-3 in Colon Epithelia.
Sarker P; Mily A; Mamun AA; Jalal S; Bergman P; Raqib R; Gudmundsson GH; Agerberth B
Antibiotics (Basel); 2014 Jul; 3(3):353-74. PubMed ID: 27025750
[TBL] [Abstract][Full Text] [Related]
13. Predicting the Risk of Clostridium difficile Infection upon Admission: A Score to Identify Patients for Antimicrobial Stewardship Efforts.
Kuntz JL; Smith DH; Petrik AF; Yang X; Thorp ML; Barton T; Barton K; Labreche M; Spindel SJ; Johnson ES
Perm J; 2016; 20(1):20-5. PubMed ID: 26845084
[TBL] [Abstract][Full Text] [Related]
14. An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.
Baliban SM; Michael A; Shammassian B; Mudakha S; Khan AS; Cocklin S; Zentner I; Latimer BP; Bouillaut L; Hunter M; Marx P; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA
Infect Immun; 2014 Oct; 82(10):4080-91. PubMed ID: 25024365
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.
De Waele JJ; Tellado JM; Weiss G; Alder J; Kruesmann F; Arvis P; Hussain T; Solomkin JS
Surg Infect (Larchmt); 2014 Oct; 15(5):567-75. PubMed ID: 24833256
[TBL] [Abstract][Full Text] [Related]
16. Effects of β-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to Clostridium difficile associated diarrhea.
Knecht H; Neulinger SC; Heinsen FA; Knecht C; Schilhabel A; Schmitz RA; Zimmermann A; dos Santos VM; Ferrer M; Rosenstiel PC; Schreiber S; Friedrichs AK; Ott SJ
PLoS One; 2014; 9(2):e89417. PubMed ID: 24586762
[TBL] [Abstract][Full Text] [Related]
17. Targeting the bacteria-host interface: strategies in anti-adhesion therapy.
Krachler AM; Orth K
Virulence; 2013 May; 4(4):284-94. PubMed ID: 23799663
[TBL] [Abstract][Full Text] [Related]
18. Modeling the role of peroxisome proliferator-activated receptor γ and microRNA-146 in mucosal immune responses to Clostridium difficile.
Viladomiu M; Hontecillas R; Pedragosa M; Carbo A; Hoops S; Michalak P; Michalak K; Guerrant RL; Roche JK; Warren CA; Bassaganya-Riera J
PLoS One; 2012; 7(10):e47525. PubMed ID: 23071818
[TBL] [Abstract][Full Text] [Related]
19. Clostridia in premature neonates' gut: incidence, antibiotic susceptibility, and perinatal determinants influencing colonization.
Ferraris L; Butel MJ; Campeotto F; Vodovar M; Rozé JC; Aires J
PLoS One; 2012; 7(1):e30594. PubMed ID: 22291996
[TBL] [Abstract][Full Text] [Related]
20. Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains.
Theriot CM; Koumpouras CC; Carlson PE; Bergin II; Aronoff DM; Young VB
Gut Microbes; 2011; 2(6):326-34. PubMed ID: 22198617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
